Patent Reform

Fighting for justice in the patent system on the ground for over 20 years in 50+ countries, we are a leading authority to address inequities in the current patent system. We're reimagining the patent system to build a more just and equitable system for all.

Why Now?

Billions of lives are literally on the line. Patents are in the national and global spotlight everyday. Disparities in access are growing more with each day. A global pandemic, economic and racial awakening, and skyrocketing drug costs create a crucial mandate that call us to act now. This is a once-in-a-generation moment to advance solutions for actionable change.

Why I-MAK?

Serving as global leaders for 20 years working with community leaders, patent offices, and drug manufacturers to increase equity in the drug patent system in over 50 countries worldwide, our strategic litigation has saved governments billions of dollars and helped provide millions of people treatment.

Our framework integrates deep analytical research, stakeholder informed collaboration, and a voice in the media to activate change through education. I-MAK is uniquely positioned with global drug patent expertise and real-world insight to advance solutions for systemic change.

Served as Advisors to
WHO
Clinton Foundation
Doctors without Borders
UNITAID
GAVI

The $111 Billion price tag Americans will pay when one drug company games the patent system - filling 422 patents on just two drugs.

16 Apr 2022

Save America's Patent System

Urgent calls to stop patent abuse are growing, and the United States’ newspaper of record has endorsed I‑MAK’s agenda for reform.

Save America's Patent System NYT
Proposed Solutions

I-MAK's framework for reforming the patent system

10 Steps to bring equity to the patent system

Timely Blueprints for Policy Change
How We Do It
Democratize the Patent System

The patent process is a “black box” with little public involvement. We aim to bring greater participation, transparency, and accountability to this process, starting with how reform is pursued and achieved. From I-MAK’s perspective, PCM is a reflection of our values; how we build toward reform is as important as the reforms themselves.

Connect Key Stakeholders

Interaction among stakeholder groups who hold different views about the role of patents in society is extremely limited. A participatory process will build much needed connection and understanding between ideologically, sectorally, and geographically diverse stakeholders, and foster a less polarized, more productive discourse around reform.

Our Research Drives Solutions

Using comprehensive research methodologies, I-MAK did a deep dive into patent and market data and compiled information that hasn't been available to the public - until now. We created a searchable database, a tool summarizing important market information on the top selling drugs, and a compelling report with key findings.

The Drug Patent Book

The Drug Patent Book

Searchable Database

This database is a user-friendly tool with comprehensive patent data on the ten top selling drugs

 Top Selling Drugs

Top Selling Drugs

Data Summary

A simple and easy resource that provides patent, pricing, spending, and market data for the ten top selling drugs in America.

 Overpatented: 2022

Overpatented: 2022

Key Findings Report

Highlights excessive patenting practices on drugs, such as Revlimid, Humira and Enbrel, which impact cancer and arthritis.

Learn more about how you can help build a more equitable system for all